Reviews citing this publication (24)
- PRC2 is high maintenance. Yu JR, Lee CH, Oksuz O, Stafford JM, Reinberg D. Genes Dev 33 903-935 (2019)
- Inhibitors of Protein Methyltransferases and Demethylases. Kaniskan HÜ, Martini ML, Jin J. Chem Rev 118 989-1068 (2018)
- WD40 repeat domain proteins: a novel target class? Schapira M, Tyers M, Torrent M, Arrowsmith CH. Nat Rev Drug Discov 16 773-786 (2017)
- Enhancer of zeste homolog 2 (EZH2) inhibitors. Gulati N, Béguelin W, Giulino-Roth L. Leuk Lymphoma 59 1574-1585 (2018)
- RNA-modifying proteins as anticancer drug targets. Boriack-Sjodin PA, Ribich S, Copeland RA. Nat Rev Drug Discov 17 435-453 (2018)
- Six Years (2012-2018) of Researches on Catalytic EZH2 Inhibitors: The Boom of the 2-Pyridone Compounds. Fioravanti R, Stazi G, Zwergel C, Valente S, Mai A. Chem Rec 18 1818-1832 (2018)
- Polycomb complexes in normal and malignant hematopoiesis. Di Carlo V, Mocavini I, Di Croce L. J Cell Biol 218 55-69 (2019)
- EZH2 abnormalities in lymphoid malignancies: underlying mechanisms and therapeutic implications. Li B, Chng WJ. J Hematol Oncol 12 118 (2019)
- Targeting Histone Methylation in Cancer. McCabe MT, Mohammad HP, Barbash O, Kruger RG. Cancer J 23 292-301 (2017)
- The Promise for Histone Methyltransferase Inhibitors for Epigenetic Therapy in Clinical Oncology: A Narrative Review. Rugo HS, Jacobs I, Sharma S, Scappaticci F, Paul TA, Jensen-Pergakes K, Malouf GG. Adv Ther 37 3059-3082 (2020)
- EZH2 inhibition: a promising strategy to prevent cancer immune editing. Kang N, Eccleston M, Clermont PL, Latarani M, Male DK, Wang Y, Crea F. Epigenomics 12 1457-1476 (2020)
- EZH2 inhibitors: a patent review (2014-2016). Stazi G, Zwergel C, Mai A, Valente S. Expert Opin Ther Pat 27 797-813 (2017)
- Dysregulated Transcriptional Control in Prostate Cancer. Baumgart SJ, Nevedomskaya E, Haendler B. Int J Mol Sci 20 E2883 (2019)
- Exploiting Epigenetic Alterations in Prostate Cancer. Baumgart SJ, Haendler B. Int J Mol Sci 18 E1017 (2017)
- Tackling malignant melanoma epigenetically: histone lysine methylation. Orouji E, Utikal J. Clin Epigenetics 10 145 (2018)
- An overview of the development of EED inhibitors to disable the PRC2 function. Liu KL, Zhu K, Zhang H. RSC Med Chem 13 39-53 (2022)
- Allosteric regulation of histone lysine methyltransferases: from context-specific regulation to selective drugs. Davidovich C, Zhang Q. Biochem Soc Trans 49 591-607 (2021)
- Domain cross-talk in regulation of histone modifications: Molecular mechanisms and targeting opportunities. Longbotham JE, Zhang MY, Fujimori DG. Curr Opin Chem Biol 57 105-113 (2020)
- Pd-Catalyzed Cross-Couplings: On the Importance of the Catalyst Quantity Descriptors, mol % and ppm. Horbaczewskyj CS, Fairlamb IJS. Org Process Res Dev 26 2240-2269 (2022)
- Polycomb Repressive Complex 2 Modulation through the Development of EZH2-EED Interaction Inhibitors and EED Binders. Tomassi S, Romanelli A, Zwergel C, Valente S, Mai A. J Med Chem 64 11774-11797 (2021)
- The pleiotropic roles of EZH2 in T-cell immunity and immunotherapy. Wang Y, Bui T, Zhang Y. Int J Hematol 116 837-845 (2022)
- The roles of EZH2 in cancer and its inhibitors. Liu Y, Yang Q. Med Oncol 40 167 (2023)
- Chemically induced degradation of epigenetic targets. Kabir M, Yu X, Kaniskan HÜ, Jin J. Chem Soc Rev 52 4313-4342 (2023)
- Exploring the therapeutic potential of targeting polycomb repressive complex 2 in lung cancer. Gao M, Li Y, Cao P, Liu H, Chen J, Kang S. Front Oncol 13 1216289 (2023)
Articles citing this publication (17)
- Degradation of Polycomb Repressive Complex 2 with an EED-Targeted Bivalent Chemical Degrader. Potjewyd F, Turner AW, Beri J, Rectenwald JM, Norris-Drouin JL, Cholensky SH, Margolis DM, Pearce KH, Herring LE, James LI. Cell Chem Biol 27 47-56.e15 (2020)
- Allosteric Activation Dictates PRC2 Activity Independent of Its Recruitment to Chromatin. Lee CH, Yu JR, Kumar S, Jin Y, LeRoy G, Bhanu N, Kaneko S, Garcia BA, Hamilton AD, Reinberg D. Mol Cell 70 422-434.e6 (2018)
- Replicational Dilution of H3K27me3 in Mammalian Cells and the Role of Poised Promoters. Jadhav U, Manieri E, Nalapareddy K, Madha S, Chakrabarti S, Wucherpfennig K, Barefoot M, Shivdasani RA. Mol Cell 78 141-151.e5 (2020)
- Discovery and Molecular Basis of a Diverse Set of Polycomb Repressive Complex 2 Inhibitors Recognition by EED. Li L, Zhang H, Zhang M, Zhao M, Feng L, Luo X, Gao Z, Huang Y, Ardayfio O, Zhang JH, Lin Y, Fan H, Mi Y, Li G, Liu L, Feng L, Luo F, Teng L, Qi W, Ottl J, Lingel A, Bussiere DE, Yu Z, Atadja P, Lu C, Li E, Gu J, Zhao K. PLoS One 12 e0169855 (2017)
- Pharmacological inhibition of EZH2 disrupts the female germline epigenome. Prokopuk L, Hogg K, Western PS. Clin Epigenetics 10 33 (2018)
- Lead Identification of 8-(Methylamino)-2-oxo-1,2-dihydroquinoline Derivatives as DNA Gyrase Inhibitors: Hit-to-Lead Generation Involving Thermodynamic Evaluation. Ushiyama F, Amada H, Takeuchi T, Tanaka-Yamamoto N, Kanazawa H, Nakano K, Mima M, Masuko A, Takata I, Hitaka K, Iwamoto K, Sugiyama H, Ohtake N. ACS Omega 5 10145-10159 (2020)
- Evaluation of EED Inhibitors as a Class of PRC2-Targeted Small Molecules for HIV Latency Reversal. Turner AW, Dronamraju R, Potjewyd F, James KS, Winecoff DK, Kirchherr JL, Archin NM, Browne EP, Strahl BD, Margolis DM, James LI. ACS Infect Dis 6 1719-1733 (2020)
- Methylation of microRNA-338-5p by EED promotes METTL3-mediated translation of oncogene CDCP1 in gastric cancer. Zhang F, Yan Y, Cao X, Zhang J, Li Y, Guo C. Aging (Albany NY) 13 12224-12238 (2021)
- Pharmacological inhibition of noncanonical EED-EZH2 signaling overcomes chemoresistance in prostate cancer. Li X, Gera L, Zhang S, Chen Y, Lou L, Wilson LM, Xie ZR, Sautto G, Liu D, Danaher A, Mamouni K, Yang Y, Du Y, Fu H, Kucuk O, Osunkoya AO, Zhou J, Wu D. Theranostics 11 6873-6890 (2021)
- Targeting the polycomb repressive complex-2 related proteins with novel combinational strategies for nasopharyngeal carcinoma. Zhu J, Li L, Tong J, Hui C, Wong CH, Lo KW, Chan R, Ai QY, Hui EP, Chan AT, To KF, Tao Q, Ma BB. Am J Cancer Res 10 3267-3284 (2020)
- Polycomb group proteins in cancer: multifaceted functions and strategies for modulation. Wang S, C Ordonez-Rubiano S, Dhiman A, Jiao G, Strohmier BP, Krusemark CJ, Dykhuizen EC. NAR Cancer 3 zcab039 (2021)
- A membrane transporter determines the spectrum of activity of a potent platinum-acridine hybrid anticancer agent. Yao X, Watkins NH, Brown-Harding H, Bierbach U. Sci Rep 10 15201 (2020)
- Targeted Degradation of PRC1 Components, BMI1 and RING1B, via a Novel Protein Complex Degrader Strategy. Park KS, Qin L, Kabir M, Luo K, Dale B, Zhong Y, Kim A, Wang GG, Kaniskan HÜ, Jin J. Adv Sci (Weinh) 10 e2205573 (2023)
- Discovery of EEDi-5273 as an Exceptionally Potent and Orally Efficacious EED Inhibitor Capable of Achieving Complete and Persistent Tumor Regression. Rej RK, Wang C, Lu J, Wang M, Petrunak E, Zawacki KP, McEachern D, Yang CY, Wang L, Li R, Chinnaswamy K, Wen B, Sun D, Stuckey JA, Zhou Y, Chen J, Tang G, Wang S. J Med Chem 64 14540-14556 (2021)
- Discovery of New Binders for DCAF1, an Emerging Ligase Target in the Targeted Protein Degradation Field. Vulpetti A, Holzer P, Schmiedeberg N, Imbach-Weese P, Pissot-Soldermann C, Hollingworth GJ, Radimerski T, Thoma CR, Stachyra TM, Wojtynek M, Maschlej M, Chau S, Schuffenhauer A, Fernández C, Schröder M, Renatus M. ACS Med Chem Lett 14 949-954 (2023)
- Insight into the Inhibitory Mechanism of Embryonic Ectoderm Development Subunit by Triazolopyrimidine Derivatives as Inhibitors through Molecular Dynamics Simulation. Ju J, Zhang H, Guan S, Liu C, Du J, Shen X, Wang S. Molecules 28 7997 (2023)
- Nicardipine is a putative EED inhibitor and has high selectivity and potency against chemoresistant prostate cancer in preclinical models. Li X, Chen Y, Bai L, Zhao R, Wu Y, Xie ZR, Wu JM, Bowen NJ, Danaher A, Cook N, Li D, Qui M, Du Y, Fu H, Osunkoya AO, Kucuk O, Wu D. Br J Cancer 129 884-894 (2023)